FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2697259651> ?p ?o ?g. }

• W2697259651 endingPage "576" @default.
• W2697259651 startingPage "571" @default.
• W2697259651 abstract "Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel. However, because of the rarity of these tumors, the standard chemotherapy regimen has not yet been established. Here, we report a case of thymic carcinoma that responded to first-line carboplatin plus nanoparticle albumin-bound paclitaxel (<i>nab</i>-paclitaxel) therapy with continuation maintenance <i>nab</i>-paclitaxel monotherapy. A 78-year-old male presented to a hospital with the chief complaint of dyspnea. Cardiomegaly was detected on chest X-ray scans, and marked pericardial effusion was observed by echocardiography. Chest computed tomography scans revealed the presence of a mediastinal mass, pericardial thickening, and pericardial effusion. The serum levels of the tumor marker CYFRA 21-1 (cytokeratin-19 fragment) were elevated. Eventually, he was diagnosed with squamous cell carcinoma of the thymus, which was staged as cT4N3M0 or stage IV (according to the tumor-node-metastasis classification). Chemotherapy with carboplatin on day 1 and <i>nab</i>-paclitaxel on days 1, 8, and 15, every 4 weeks was initiated. After the administration of 4 cycles of this regimen, the tumor diameter appeared reduced, and the serum CYFRA 21-1 levels were normalized. After a 1-month interval, the serum CYFRA 21-1 levels increased again; therefore, maintenance <i>nab</i>-paclitaxel monotherapy was initiated. At the end of the treatment, the patient experienced a progression-free survival of 10.3 months. Carboplatin plus <i>nab</i>-paclitaxel may be an appropriate alternative first-line treatment for thymic carcinomas. Additionally, maintenance <i>nab</i>-paclitaxel monotherapy may prolong the progression-free survivals of patients with thymic carcinomas." @default.
• W2697259651 created "2017-06-30" @default.
• W2697259651 creator A5017558125 @default.
• W2697259651 creator A5029146597 @default.
• W2697259651 creator A5039801880 @default.
• W2697259651 creator A5042086172 @default.
• W2697259651 creator A5049495355 @default.
• W2697259651 creator A5055004912 @default.
• W2697259651 creator A5055456183 @default.
• W2697259651 creator A5077441013 @default.
• W2697259651 date "2017-06-23" @default.
• W2697259651 modified "2023-09-23" @default.
• W2697259651 title "First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report" @default.
• W2697259651 cites W1996654617 @default.
• W2697259651 cites W2012510274 @default.
• W2697259651 cites W2042515268 @default.
• W2697259651 cites W2053295326 @default.
• W2697259651 cites W2088371419 @default.
• W2697259651 cites W2090272732 @default.
• W2697259651 cites W2090914388 @default.
• W2697259651 cites W2109063316 @default.
• W2697259651 cites W2130819399 @default.
• W2697259651 cites W2154371663 @default.
• W2697259651 cites W2164067249 @default.
• W2697259651 cites W2165080745 @default.
• W2697259651 cites W2166624818 @default.
• W2697259651 cites W2296427641 @default.
• W2697259651 cites W4230103308 @default.
• W2697259651 doi "https://doi.org/10.1159/000477758" @default.
• W2697259651 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5567109" @default.
• W2697259651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28868014" @default.
• W2697259651 hasPublicationYear "2017" @default.
• W2697259651 type Work @default.
• W2697259651 sameAs 2697259651 @default.
• W2697259651 citedByCount "4" @default.
• W2697259651 countsByYear W26972596512020 @default.
• W2697259651 countsByYear W26972596512022 @default.
• W2697259651 countsByYear W26972596512023 @default.
• W2697259651 crossrefType "journal-article" @default.
• W2697259651 hasAuthorship W2697259651A5017558125 @default.
• W2697259651 hasAuthorship W2697259651A5029146597 @default.
• W2697259651 hasAuthorship W2697259651A5039801880 @default.
• W2697259651 hasAuthorship W2697259651A5042086172 @default.
• W2697259651 hasAuthorship W2697259651A5049495355 @default.
• W2697259651 hasAuthorship W2697259651A5055004912 @default.
• W2697259651 hasAuthorship W2697259651A5055456183 @default.
• W2697259651 hasAuthorship W2697259651A5077441013 @default.
• W2697259651 hasBestOaLocation W26972596511 @default.
• W2697259651 hasConcept C121608353 @default.
• W2697259651 hasConcept C126322002 @default.
• W2697259651 hasConcept C126894567 @default.
• W2697259651 hasConcept C141071460 @default.
• W2697259651 hasConcept C143998085 @default.
• W2697259651 hasConcept C2776349617 @default.
• W2697259651 hasConcept C2776694085 @default.
• W2697259651 hasConcept C2777292972 @default.
• W2697259651 hasConcept C2777511904 @default.
• W2697259651 hasConcept C2777546739 @default.
• W2697259651 hasConcept C2778239845 @default.
• W2697259651 hasConcept C2778336483 @default.
• W2697259651 hasConcept C2779126056 @default.
• W2697259651 hasConcept C2781175549 @default.
• W2697259651 hasConcept C2781413609 @default.
• W2697259651 hasConcept C2781451048 @default.
• W2697259651 hasConcept C530470458 @default.
• W2697259651 hasConcept C71924100 @default.
• W2697259651 hasConcept C90924648 @default.
• W2697259651 hasConceptScore W2697259651C121608353 @default.
• W2697259651 hasConceptScore W2697259651C126322002 @default.
• W2697259651 hasConceptScore W2697259651C126894567 @default.
• W2697259651 hasConceptScore W2697259651C141071460 @default.
• W2697259651 hasConceptScore W2697259651C143998085 @default.
• W2697259651 hasConceptScore W2697259651C2776349617 @default.
• W2697259651 hasConceptScore W2697259651C2776694085 @default.
• W2697259651 hasConceptScore W2697259651C2777292972 @default.
• W2697259651 hasConceptScore W2697259651C2777511904 @default.
• W2697259651 hasConceptScore W2697259651C2777546739 @default.
• W2697259651 hasConceptScore W2697259651C2778239845 @default.
• W2697259651 hasConceptScore W2697259651C2778336483 @default.
• W2697259651 hasConceptScore W2697259651C2779126056 @default.
• W2697259651 hasConceptScore W2697259651C2781175549 @default.
• W2697259651 hasConceptScore W2697259651C2781413609 @default.
• W2697259651 hasConceptScore W2697259651C2781451048 @default.
• W2697259651 hasConceptScore W2697259651C530470458 @default.
• W2697259651 hasConceptScore W2697259651C71924100 @default.
• W2697259651 hasConceptScore W2697259651C90924648 @default.
• W2697259651 hasIssue "2" @default.
• W2697259651 hasLocation W26972596511 @default.
• W2697259651 hasLocation W26972596512 @default.
• W2697259651 hasLocation W26972596513 @default.
• W2697259651 hasLocation W26972596514 @default.
• W2697259651 hasLocation W26972596515 @default.
• W2697259651 hasOpenAccess W2697259651 @default.
• W2697259651 hasPrimaryLocation W26972596511 @default.
• W2697259651 hasRelatedWork W1982849070 @default.
• W2697259651 hasRelatedWork W2012171803 @default.
• W2697259651 hasRelatedWork W2025352271 @default.
• W2697259651 hasRelatedWork W2051573328 @default.

• next